Drug Trial Radar · NCT07122401
Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
424
Planned (sponsor's estimate)
Start
Sep 30, 2025
Primary completion
Nov 26, 2026
Study completion Nov 26, 2026
Sponsor
- Lead sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MT1013 is a first-in-class dual-target agonist. This study is a multicenter, randomized, double-blind, double-dummy phase III clinical study being conducetd to evaluate the efficacy and safety of MT1013 compared with active control cinacalcet in secondary hyperparathyroidism patients on maintenance dialysis. Subjects will be 1:1 randomized to receive MT1013 or cinacalcet for 26 weeks. Evaluations of iPTH, Ca, P, BMD, and biomarkers will be done across the study period, to compare efficacy and safety of MT1013 to cinacalcet.
Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
Interventions
MT1013Drug
MT1013 + dummy cinacalcet
CinacalcetDrug
Cinacalcet + dummy MT1013
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants with > 50% reduction from baseline in mean intact parathyroid (iPTH)Time frame: EAP(Week 22-27)
- Percentage of participants with > 30% reduction from baseline in mean iPTHTime frame: EAP(Week 22-27)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.